Sensitivity to a specific inhibitor (e.g., venetoclax or other BH3 mimetics) is then used to infer the reliance of a tumor (e.g., CLL) on one or more pro-survival BCL2 proteins. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.